Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
01/11/2026 01:00 PM • Krystal Biotech reported preliminary 4Q 2025 VYJUVEK net revenue of $106-107 million and full-year 2025 revenue of $388-389 million. The company outlined an ambitious strategic vision to become a global leader in rare disease with plans to launch at least four marketed medicines by 2030, treating over 10,000 patients. The company maintains a strong balance sheet with $955 million in cash and investments, and expects combined non-GAAP R&D and SG&A expenses of $175-195 million in 2026.
KRYS - The company demonstrated strong commercial execution with VYJUVEK generating $388-389 million in full-year 2025 revenue, successful European and Japanese launches, a robust clinical pipeline with multiple potential blockbuster launches expected within four years, a solid balance sheet of $955 million, and ambitious growth targets including four marketed medicines by 2030. The expansion of the KB801 registrational study and multiple clinical milestones planned for 2026 further support positive momentum.